GlassScriptPhysician profile
Phyllis Tarallo
NPI 1043217300
$6,229.56
in general payments reported to CMS, 2019-2025
37 companies · $3,989 in 2025
The $3,989 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $384 · 2023: $690 · 2024: $913 · 2025: $3,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,585 · Education: $608 · Long Term Medical Supply Or Device Loan: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,585.24 |
| Education | $607.90 |
| Long Term Medical Supply Or Device Loan | $398.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $894.51 | 2021-2025 | |
| Gilead Sciences, INC. | $535.37 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $440.83 | 2024-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $438.35 | 2024-2025 | Enhertu, Injectafer, Vanflyta |
| Glaxosmithkline, LLC. | $403.19 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $336.23 | 2022-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $312.52 | 2024-2025 | Lynparza, Enhertu, Tagrisso |
| Lilly USA, LLC | $285.27 | 2021-2025 | Verzenio, Jaypirca |
| Taiho Oncology, INC. | $228.19 | 2024-2025 | |
| Janssen Biotech, INC. | $215.18 | 2023-2025 | Erleada, Balversa, Tecvayli |
| Eisai INC. | $207.65 | 2021-2025 | |
| Abbvie INC. | $190.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.02 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $157.21 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Emd Serono, INC. | $129.72 | 2023-2025 | Bavencio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $126.78 | 2022-2023 | Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $103.53 | 2025 | |
| Celgene Corporation | $99.87 | 2023-2025 | Reblozyl |
| Puma Biotechnology, INC. | $93.04 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $90.84 | 2025 | |
| Astellas Pharma US INC | $90.55 | 2022-2025 | Padcev, Xospata, Vyloy |
| Pfizer INC. | $90.16 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $87.38 | 2023-2025 | Monoferric, Cosela |
| Ipsen Biopharmaceuticals, INC | $75.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.68 | 2023-2025 | Fruzaqla, Alunbrig |
| Sumitomo Pharma America, INC. | $64.19 | 2023-2025 | Orgovyx |
| Genmab U.S., INC. | $45.80 | 2025 | Epkinly |
| Servier Pharmaceuticals LLC | $40.98 | 2024-2025 | |
| Genzyme Corporation | $40.49 | 2022-2023 | |
| Stemline Therapeutics INC. | $37.91 | 2023-2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2025 | |
| Sobi, INC | $18.39 | 2023 | |
| Verastem, INC. | $18.05 | 2025 | Avmapki Fakzynja Co-Pack |
| Mirati Therapeutics, INC. | $14.99 | 2024 | Krazati |
| Acrotech Biopharma INC. | $14.49 | 2024 | Ryzneuta |
| Amgen INC. | $14.30 | 2023 | Kyprolis |
| Myovant Sciences INC. | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Tarallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.